FDA-regulated · Physician-prescribed · United States

Psychedelic medicine
treatment that cures.

idelic connects you with licensed physicians to access FDA-approved psychedelic treatments at partner clinics.
Treatment scheduled to launch in late 2026.

US patients only · No spam · We'll notify you when treatment opens near you.

Why now

For decades, the same antidepressants.
The same waiting. The same "let's try a higher dose."
For millions living with depression, anxiety,
PTSD, and addiction — it hasn't worked.
The science has moved on. So have we.

Four compounds — psilocybin, LSD, DMT, and ibogaine — are producing remission rates in peer-reviewed trials that conventional psychiatry has never seen. We're building the platform to make them accessible.

Four molecules.
Decades of evidence.

Click any card to read the history and clinical data. Hover underlined terms for definitions.
NDA Filed
Psilocybin
Found in fungi for thousands of years
"A single session produced remission in 29% of patients where multiple antidepressants had failed."
⏱ Expected FDA approval: 2026
−12.3
MADRS?
MADRS
The Montgomery-Åsberg Depression Rating Scale (0–60). Higher scores = more severe depression. A clinically meaningful response is typically a ≥50% reduction. A drop of 10+ points is considered significant. It's the gold standard scale used in FDA antidepressant trials.
 point reduction vs. placebo (JAMA, 2023)
29%
Remission rate in Phase 3 TRD trial (2024). SSRIs average ~15–20% in TRD populations.
History
Psilocybin has been used in Mesoamerican spiritual practices for over 3,000 years. Modern research began in the 1950s when Swiss chemist Albert Hofmann first isolated it from Psilocybe mushrooms. Following decades of prohibition after the Controlled Substances Act (1970), clinical research resumed at Johns Hopkins and NYU in the 2000s, culminating in FDA Breakthrough Therapy designation in 2018 — the fastest regulatory pathway available.
Clinical efficacy vs. SSRIs
Phase 2 trial (NEJM, 2021): psilocybin vs. escitalopram — equivalent MADRS reduction, but psilocybin produced superior outcomes on well-being, meaning, and joy metrics (Carhart-Harris et al.)
JAMA 2023 RCT: single psilocybin dose reduced MADRS by 12.3 points more than placebo at day 43 — comparable to best-performing SSRIs at 8 weeks, but achieved in a single session
22% higher response rate than SSRI-treated patients in head-to-head Phase 2 comparison (Goodwin et al., 2023)
54% of patients met MADRS remission criteria (score ≤10) after a single moderate dose (von Rotz et al., eClinicalMedicine, 2023)
Sources: NEJM 2021; JAMA 2023; eClinicalMedicine 2023; Neuropsychopharmacology 2023
Regulatory timeline
NDA filed — approval expected late 2026
Phase 3 Trials Underway
LSD
Lysergic acid diethylamide — synthesised 1938
"MADRS scores reduced by 59.5% — and sustained for six months — with a microdosing protocol."
⏱ Expected FDA approval: 2027
−59.5%
MADRS?
MADRS
The Montgomery-Åsberg Depression Rating Scale (0–60). Higher scores = more severe depression. A clinically meaningful response is typically a ≥50% reduction. A drop of 10+ points is considered significant. It's the gold standard scale used in FDA antidepressant trials.
 score reduction at end of 8-week protocol (Univ. Auckland, 2025)
6 mo
Sustained remission after 8-week microdosing protocol — effects still measurable at 6-month follow-up.
History
LSD was first synthesised by Albert Hofmann at Sandoz Laboratories in 1938, and its psychoactive properties were discovered accidentally in 1943. Throughout the 1950s and 1960s, it was the subject of over 1,000 published clinical studies across more than 40,000 patients, primarily for anxiety, addiction, and depression. Research was halted by Schedule I classification in 1970. Modern clinical trials resumed in the 2010s, with MindMed receiving FDA Breakthrough Therapy designation for MM120 (LSD) in anxiety disorder in 2023.
Clinical efficacy data
LSD microdosing for MDD (8-week regimen): 59.5% reduction in MADRS scores, sustained to 6 months. 9 of 19 participants met criteria for full remission (Univ. Auckland, Neuropharmacology 2025)
HAM-A (anxiety) decreased 51.9% in same cohort — addressing comorbid anxiety where SSRIs often worsen symptoms initially
MM120 Phase 2b RCT (JAMA, 2024): MADRS score improvement of 6.4 points vs. placebo at Week 12 (p≤0.05). CGI-S improved from 'markedly ill' to 'borderline ill' — a two-category clinical shift
Phase 3 trial for MM120 now underway (NCT06941844), targeting anxiety and depression
Sources: Neuropharmacology 2025; JAMA 2024; clinicaltrials.gov
Regulatory timeline
Phase 3 underway — est. NDA filing 2027, approval 2028
Phase 2a — Nature Medicine, Feb 2026
DMT
Dimethyltryptamine — endogenous psychedelic
"A 25-minute session produced antidepressant effects lasting up to six months. One dose may suffice."
⏱ Expected FDA approval: 2028
d=1.09
Cohen's d?
Cohen's d effect size
d = 1.09 is a large effect — measures how much better DMT performed vs. placebo in standard deviations. Most SSRIs score d ≈ 0.3–0.4. DMT's d=1.09 at 1 week exceeds most psilocybin trial results.
 effect size at 1 week (Nature Medicine, 2026)
85.7%
Response rate in TRD open-label trial. Remission rate 57.1% at 7 days. Effects lasted up to 3 months.
History
DMT is an endogenous compound found naturally in the human brain, lung, and blood. It has been used for centuries in ayahuasca preparations by Amazonian indigenous communities for healing and spiritual purposes. Modern pharmacological study began with Dr. Rick Strassman's landmark DMT research at University of New Mexico in the 1990s. Unlike other psychedelics, DMT's ultra-short half-life (~5 minutes) makes it potentially the most clinically practical psychedelic — sessions last 25–30 minutes rather than 4–8 hours.
Clinical efficacy data
Phase 2a RCT (Imperial College London, Nature Medicine Feb 2026): single IV DMT vs. placebo in 34 MDD patients — MADRS 10.75 points larger reduction than placebo at 1 week (p=0.002). Effect size d=1.09 at 1 week
Effects persisted for up to 3 months (some up to 6 months) from a single dose. No significant difference between one vs. two doses — one session may be sufficient
Open-label TRD trial (vaporized DMT, Brazil): average MADRS reduction of 21.14 points at day 7 (p<0.001). Response 85.7%, remission 57.1%. Suicidal ideation fell significantly within 24 hours (Falchi-Carvalho et al., Neuropsychopharmacology 2025)
Practical advantage: DMT does not require discontinuation of existing antidepressants, unlike standard psilocybin protocols
Sources: Nature Medicine 2026 (Imperial/Cybin UK); Neuropsychopharmacology 2025; Psychedelic Medicine 2025
Regulatory timeline
Phase 2a complete — Phase 3 expected 2026/27, approval ~2029–30
Phase 1 (cardiac-safe analog) — NIH funded
Ibogaine
From Tabernanthe iboga — West African ceremonial plant
"Veterans showed 81–88% reductions in depression, PTSD and anxiety. No other treatment comes close."
⏱ Expected FDA approval: 2029
−88%
MADRS?
MADRS
The Montgomery-Åsberg Depression Rating Scale (0–60). Higher scores = more severe depression. A clinically meaningful response is typically a ≥50% reduction. A drop of 10+ points is considered significant. It's the gold standard scale used in FDA antidepressant trials.
 score reduction in TBI veterans observational study (Nature Medicine, 2024)
83–86%
Remission rate across depression, PTSD & anxiety in same cohort. Cardiac-safe analog now in Phase 1 trials.
History
Ibogaine is derived from the root bark of Tabernanthe iboga, a shrub native to Central and West Africa used for centuries in Bwiti spiritual initiation ceremonies. Western scientific interest began in the 1960s when Howard Lotsof discovered it dramatically interrupted heroin withdrawal. It was briefly marketed as an antidepressant in France before being placed under Schedule I in the US in 1970. Today it is used legally in clinics in Mexico, the Netherlands, and other countries. Texas allocated $50 million for ibogaine research in veterans in 2025, reflecting growing political momentum.
Clinical efficacy data
Veterans with traumatic brain injury (Nature Medicine, 2024, Stanford): ibogaine treatment produced MADRS reductions of up to 88%, and PTSD/anxiety scores (CAPS-5, HAM-A) reduced by 81–88%, with remission rates of 83–86%
Disability score (WHODAS) dropped from 30 (mild-moderate disability) to 5 (no disability) one month post-treatment — a near-complete functional recovery
Primary barrier to FDA approval: cardiotoxicity risk. Gilgamesh Pharmaceuticals is developing GM-3009, a cardiac-safe ibogaine analog, funded by a $14 million NIH/NIDA grant — currently in Phase 1 safety trials
If GM-3009 clears Phase 1 safely, Phase 2/3 trials expected 2027–2029, with potential FDA filing ~2030–2031
Sources: Nature Medicine 2024 (Stanford); Gilgamesh/NIDA 2024; Texas SB 1057 (2025)
Regulatory timeline
Phase 1 (analog) underway — approval est. 2030–2032

It's a new dawn.

It's a new day.

Access is opening.

Now the journey begins.

What we do

From intake
to integration.
We're with you.

01

Clinical intake

A structured digital intake covering your diagnosis, treatment history, and health background. Reviewed by a licensed physician before anything proceeds — no prescription without a thorough, documented assessment.

02

Physician evaluation

A telemedicine consultation with an affiliated physician determines whether treatment is appropriate and builds your personalised care protocol. Treatment is initiated only when clinically warranted.

03

Supervised session

Treatment takes place at a certified partner clinic. A trained clinical guide is present throughout. Biometrics are monitored in real time and reviewed by your physician. Outcomes measured with validated scales at defined intervals.

04

Integration therapy

The session is only the beginning. Structured integration sessions with a licensed therapist help you process insights, anchor behavioural change, and sustain the therapeutic gains — the step most programmes skip and research shows is critical for durability.

Common questions

Answers to
common questions.

Yes — when prescribed by a licensed physician under the appropriate regulatory pathway, these treatments are legal. Esketamine (a ketamine derivative) is already FDA-approved. Psilocybin has FDA Breakthrough Therapy designation and an NDA filed, meaning FDA approval could come in 2026. All treatments on the idelic platform will only be offered once FDA-approved and only through licensed physicians operating within state medical law. We are not a recreational service and we are not operating outside of federal or state regulations.
We're targeting a 2026 launch, beginning in states with the most progressive regulatory frameworks — Oregon, Colorado, California, and New York are likely first. Federal FDA approval unlocks access nationally, but individual states still govern how treatments are administered. Joining the waitlist tells us where demand is highest, which directly influences where we open first. We'll notify you the moment access opens in your state.
Not immediately — but this is changing faster than most people realise. Insurance coverage typically follows FDA approval by 1–3 years. Esketamine (Spravato) already has insurance coverage through most major carriers for treatment-resistant depression. Once psilocybin receives FDA approval, coverage precedents from esketamine will accelerate the process. In the meantime, we're working with financing partners to ensure cost is not a barrier, and we'll publish transparent pricing well before launch.
In a supervised clinical setting, the safety profile of psychedelic-assisted therapy is strong. Phase 3 trials report that the most common side effects are transient — nausea, headache, and elevated heart rate during the session itself, typically resolving within hours. Serious adverse events are rare and substantially lower than the long-term side effect profiles of SSRIs (weight gain, sexual dysfunction, emotional blunting). Critically, these are not recreational doses taken alone — they're controlled doses administered in a monitored clinical environment with a trained guide present throughout. The risk profile changes dramatically in that context.
The differences are fundamental — set, setting, dose, and support determine the outcome. Clinical psychedelic therapy involves a precisely calibrated dose (not "eyeballed"), a purpose-designed therapeutic environment, a trained guide present throughout the experience, and structured integration therapy afterwards. The research consistently shows that integration — the process of making meaning from the experience — accounts for a significant portion of the therapeutic benefit. Recreational use has none of these elements. The clinical results we reference on this page were produced under exactly these controlled conditions, not from recreational use.
Join the waitlist

Be first.
When it opens.

Treatment launching in 2026. We'll notify you the moment access opens in your state.

Medical disclaimer: idelic is a technology platform, not a medical provider. All clinical services are delivered by independent licensed physicians. No compound referenced on this page has received FDA approval for the indication described except where stated. Clinical data is sourced from peer-reviewed publications; individual results vary and early-phase trial results should be interpreted with appropriate caution. This page is for informational purposes only and does not constitute a medical recommendation. If you are experiencing a mental health crisis, please contact the 988 Suicide & Crisis Lifeline.

Privacy Policy

Last updated: February 2026 · Draft — consult a healthcare attorney before publishing

Who we are

idelic is a technology platform that connects patients with licensed physicians for evaluation and coordination of psychedelic-assisted treatments. We are not a medical provider. Our full legal entity details will be listed here prior to launch.

What we collect

Why we collect it

Data storage & security

Your data is stored securely with encryption at rest and in transit. We do not sell or share your personal information with third parties, except as required to operate the service (e.g. transactional email providers).

Your rights

Contact

For privacy questions or to exercise your rights: [email protected]

This is a working draft. idelic will publish a final attorney-reviewed privacy policy prior to launch.

Terms of Service

Last updated: February 2026 · Draft — consult an attorney before publishing

About idelic

idelic is a technology platform that provides information about psychedelic-assisted treatments and connects interested patients with licensed physicians. idelic is not a medical provider, does not provide medical advice, and does not prescribe treatments.

Eligibility

You must be at least 18 years old and a resident of the United States to use this service. By joining the waitlist you confirm that you meet these requirements.

Not medical advice

All information on this site is for informational purposes only. Nothing on idelic.com constitutes medical advice, a diagnosis, or a treatment recommendation. Always consult a licensed physician before making any medical decisions. If you are experiencing a mental health crisis, please contact the 988 Suicide & Crisis Lifeline immediately.

Clinical data & accuracy

We make every effort to accurately represent published peer-reviewed research. Clinical trial results represent population averages and individual outcomes will vary. No compound referenced on this site has received FDA approval for the indication described except where explicitly stated.

Waitlist

Joining the waitlist does not guarantee access to treatment, create a patient-provider relationship, or constitute a contract of any kind. We reserve the right to change, pause, or discontinue the waitlist at any time.

Limitation of liability

To the fullest extent permitted by law, idelic shall not be liable for any indirect, incidental, or consequential damages arising from your use of this site or reliance on information contained herein.

Governing law

These terms are governed by the laws of the State of Delaware, United States, without regard to conflict of law principles.

Changes to these terms

We may update these terms from time to time. Continued use of the site after changes constitutes acceptance of the revised terms.

Contact

Questions about these terms: [email protected]

This is a working draft. idelic will publish a final attorney-reviewed Terms of Service prior to launch.

Get in touch

We read every message. Expect a reply within 2 business days.

You're on the waitlist — we'll be in touch.